Business
Novo Nordisk Shares Crater 15% as Weight-Loss Trial Misses Eli Lilly Benchmark
Novo Nordisk stock plummeted on Monday following clinical trial results that failed to match the efficacy of Eli Lilly’s competing weight-loss treatment. The market reaction coincides with significant structural changes at Merck as pharmaceutical giants face mounting sales pressure.
February 23, 2026825 views
Score0
Enjoyed this story? Share it! 👇
Advertisement
Related Stories
Business
Wellness Franchises Drive 2026 Economic Growth as Membership Models Replace Fast Food Dominance
1d ago
Business
Morgan Wallen Secures Twentieth No. 1 with '20 Cigarettes' as Country Airplay Milestone Reshapes History
1d ago
Business
Michael Burry Issues 'Catastrophic' Risk Warning Over Nvidia Market Position
1d ago
Business
The Quarter-Salary Sacrifice: New Study Reveals the Steep Price Workers Pay for Remote Freedom
1d ago
Comments (3)
Sign in to leave a comment.
Grace Coleman4d ago
A 15% drop feels
Kavya Menon4d ago
It is fascinating to
Tyler Reed4d ago
It is quite a dramatic